ReviewDiseases (Basel, Switzerland)2026
Optimizing Aortic Valve Replacement Through Strategic Upsizing: A Modern Framework for Lifetime Valve Management.
Review in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aortic valve disease is increasingly recognized as a chronic, progressive condition in which the initial valve intervention exerts a decisive influence on all subsequent therapeutic options. The persistence of prosthesis-patient mismatch (PPM), often driven by implantation of small surgical prostheses (≤21-23 mm), is associated with higher residual transvalvular gradients, attenuated left ventricular reverse remodeling, inferior long-term survival, and compromised outcomes following valve-in-valve (ViV) transcatheter procedures. Accumulating clinical and imaging evidence indicates that aortic annular enlargement (AAE), particularly using contemporary Y-incision and extended "roof" reconstruction techniques, can safely and reproducibly expand the annulus, sinuses of Valsalva, and sinotubular junction, thereby permitting implantation of larger prostheses and substantially reducing the risk of PPM. Insights from computational fluid dynamics further demonstrate that annular and root enlargement favorably alters postoperative flow dynamics, resulting in lower peak velocities, reduced pressure gradients, and more physiologic flow patterns in both primary surgical valve replacement and simulated ViV settings. From a lifetime management perspective, valve diameter optimization emerges as a critical determinant of both immediate hemodynamic performance and future procedural feasibility. Surgical programs that adopt a systematic approach to anatomic assessment, valve sizing strategy, PPM surveillance, and ViV preparedness may achieve meaningful improvements in short- and long-term outcomes. This review integrates anatomic, operative, hemodynamic, and quality-oriented evidence to support consideration of valve upsizing as a central principle in contemporary aortic valve replacement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.